Abgenix, Gliatech deal

ABGX received exclusive worldwide development and marketing rights to human monoclonal antibodies against complement protein properdin from GLIA for all indications, including cardiovascular and inflammatory diseases. Under a 2000 deal, ABGX used its XenoMouse technology to produce the anti-properdin antibodies, and GLIA had rights to resulting products (see BioCentury, Jan. 24, 2000). GLIA said it is not an antibody development company, and wanted a partner for the properdin antibodies . ...